"(S)-N-Ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine"@en . "Well-absorbed from the gastrointestinal tract."@en . . . "(+)-fenfluramine"@en . . . . . " "@en . "Dexfenfluraminum"@en . . "D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine"@en . . . "Humans and other mammals"@en . . "17-20 hours"@en . . . . "Dextrofenfluramine"@en . . . "approved"@en . . . . . "Dexfenfluramina"@en . . "36%"@en . "Symptoms of overdose include respiratory failure and cardiac arrest leading to death."@en . "Dexfenfluramine"@en . "Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates."@en . . . "illicit"@en . . . . "3239-44-9"@en . "(S)-fenfluramine"@en . . "Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn."@en . . . . . . "Take with meals."@en . . . "withdrawn"@en . "Dexfenfluramine"@en . . . . "For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet"@en . .